156 related articles for article (PubMed ID: 11707823)
1. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity.
Duvic M; Feasel AM; Schwartz CA; Cather JC
Clin Lymphoma; 2000 Sep; 1(2):141-5. PubMed ID: 11707823
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
Su IJ; Tsai TF; Cheng AL; Chen CC
J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
[TBL] [Abstract][Full Text] [Related]
3. Mycosis on mycosis fungoides: zoophilic dermatophytosis selectively superimposed on pre-existing cutaneous T-cell lymphoma (mycosis fungoides) plaques.
Capella GL; Altomare GF
Mycoses; 2003 Feb; 46(1-2):67-70. PubMed ID: 12588488
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
5. Granulomatous slack skin: a distinct disorder or a variant of mycosis fungoides?
Topar G; Zelger B; Schmuth M; Romani N; Thaler J; Sepp N
Acta Derm Venereol; 2001; 81(1):42-4. PubMed ID: 11411914
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the skin microbiome in cutaneous T-cell lymphoma delays tumour growth and increases survival in the murine EL4 model.
Dey S; Vieyra-Garcia PA; Joshi AA; Trajanoski S; Wolf P
Front Immunol; 2024; 15():1255859. PubMed ID: 38646524
[TBL] [Abstract][Full Text] [Related]
7. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Bonefeld CM; Wasik MA; Koralov SB; Geisler C; Kilian M; Iversen L; Woetmann A; Odum N
Toxins (Basel); 2013 Aug; 5(8):1402-21. PubMed ID: 23949004
[TBL] [Abstract][Full Text] [Related]
8. Approach to lymphoproliferative infiltrates of the skin. The difficult lesions.
Kempf W; Dummer R; Burg G
Am J Clin Pathol; 1999 Jan; 111(1 Suppl 1):S84-93. PubMed ID: 9894473
[TBL] [Abstract][Full Text] [Related]
9. Infectious agents in cutaneous T-cell lymphoma.
Mirvish ED; Pomerantz RG; Geskin LJ
J Am Acad Dermatol; 2011 Feb; 64(2):423-31. PubMed ID: 20692726
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
[TBL] [Abstract][Full Text] [Related]
11. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Heald PW; Glusac EJ
J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):283-5. PubMed ID: 10642687
[TBL] [Abstract][Full Text] [Related]
12. CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency.
Gammon B; Robson A; Deonizio J; Arkin L; Guitart J
J Am Acad Dermatol; 2014 Sep; 71(3):555-60. PubMed ID: 24813299
[TBL] [Abstract][Full Text] [Related]
13. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
14. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
15. Follicular cutaneous T-cell lymphoma: a clinicopathological study of nine cases.
Hodak E; Feinmesser M; Segal T; Yosipovitch G; Lapidoth M; Maron L; Bergman R; Sahar D; David M
Br J Dermatol; 1999 Aug; 141(2):315-22. PubMed ID: 10468808
[TBL] [Abstract][Full Text] [Related]
16. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
18. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
19. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous pseudo-T-cell lymphomas. A clinicopathologic study of 20 patients.
Rijlaarsdam JU; Scheffer E; Meijer CJ; Willemze R
Cancer; 1992 Feb; 69(3):717-24. PubMed ID: 1730122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
